xamoterol has been researched along with scopolamine hydrobromide in 3 studies
| Studies (xamoterol) | Trials (xamoterol) | Recent Studies (post-2010) (xamoterol) | Studies (scopolamine hydrobromide) | Trials (scopolamine hydrobromide) | Recent Studies (post-2010) (scopolamine hydrobromide) |
|---|---|---|---|---|---|
| 269 | 80 | 17 | 7,548 | 563 | 1,401 |
| Protein | Taxonomy | xamoterol (IC50) | scopolamine hydrobromide (IC50) |
|---|---|---|---|
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.003 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.006 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.006 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.006 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0006 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.006 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.006 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0026 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
3 other study(ies) available for xamoterol and scopolamine hydrobromide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |